Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis

New HIV-1 infection rates far outpace the targets set by global health organizations, despite important progress in curbing the progression of the epidemic. Long-acting (LA) formulations delivering antiretroviral (ARV) agents for HIV-1 pre-exposure prophylaxis (PrEP) hold significant promise, potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunawardana, Manjula, Remedios-Chan, Mariana, Sanchez, Debbie, Webster, Simon, Galvan, Patricia, Fanter, Rob, Castonguay, Amalia E., Webster, Paul, Moss, John A., Kuo, Joseph, Gallay, Philippe A., Vincent, Kathleen L., Motamedi, Massoud, Weinberger, Dana, Marzinke, Mark A., Hendrix, Craig W., Baum, Marc M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849190/
https://www.ncbi.nlm.nih.gov/pubmed/33536904
http://dx.doi.org/10.3389/fphar.2020.569373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849190/
https://www.ncbi.nlm.nih.gov/pubmed/33536904
http://dx.doi.org/10.3389/fphar.2020.569373

Ejemplares similares